A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

(2015) J. O'Shaughnessy et al.   ANNALS OF ONCOLOGY

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

(2015) Charles J Ryan et al.   LANCET ONCOLOGY

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

(2013) A. Gucalp et al.   CLINICAL CANCER RESEARCH

Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?

(2012) T. E. Hickey et al.   MOLECULAR ENDOCRINOLOGY

Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer

(2011) Min Ni et al.   CANCER CELL

Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1

(2011) Jessica L L Robinson et al.   EMBO JOURNAL

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study

(2011) Laura C Collins et al.   MODERN PATHOLOGY

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

A refined molecular taxonomy of breast cancer

(2011) M Guedj et al.   ONCOGENE

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

(2010) Daniel C. Danila et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

(2008) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY